EMA committee recommends drug candidate from Ascendis Pharma
The European Medicines Agency’s (EMA) advisory panel, CHMP, recommends approval of drug candidate TransCon PTH (palopegteriparatide), developed by Danish-American biotech company Ascendis Pharma, the company writes in an announcement on Friday morning.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
FDA points out shortcomings in Ascendis application
For subscribers